IMCD reports 28% EBITA growth in the first three months of 2021
Rotterdam, The Netherlands (29 April 2021) - IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces its first three months 2021 results.
- Gross profit growth of 12% to EUR 197.6 million (+17% on a constant currency basis)
- Operating EBITA increase of 28% to EUR 90.6 million (+34% on a constant currency basis)
- Net result before amortisation and non-recurring items increase of 27% to EUR 63.8 million (+32% on a constant currency basis)
- Cash earnings per share increased by 18% to EUR 1.11 (first three months of 2020: EUR 0.94)
- Further strengthening of the pharma, food, and personal care activities in EMEA by the completion of three acquisitions (Ejder Kimya, Siyeza Fine Chem Propriety Limited, and the pharmaceutical business of Peak International Products B.V.)
Piet van der Slikke, CEO:"I am pleased to report that IMCD had a strong start of the year. Our team performed excellently despite challenges from Covid, product shortages and disturbances in supply chains. We experienced strong demand in particular in the industrial sector. Acquisitions completed last year performed in accordance with expectations. This resulted in an operating EBITA growth of 28% (+34% on a constant currency base) and in favourable development of other KPI’s as well. Free cash flow grew to EUR 63.6 million (+91%) and cash earnings per share was up 18%. All regions contributed to these results. We continue to execute our strategy diligently by working hard on further digitalising our business, providing sustainable product solutions to our customers, and strengthening our presence in various markets. With this promising start, I am optimistic that the quality of our staff and the strength of our business model enables IMCD to further grow its business this year."
Attached, please find the full press release.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Novo Nordisk A/S – Share repurchase programme7.5.2021 21:31:30 CEST | Press release
Bagsværd, Denmark, 7May2021 — As part of the up to DKK 18 billion 2021 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to DKK 3.3 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). For that purpose, Novo Nordisk A/S has appointed Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB, as lead manager to execute the programme independently and without influence from Novo Nordisk A/S. The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. Under the agreement, Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB, will repurchase B shares on behalf of Novo Nordisk A/S during the trading period starting 10 May 20
Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme7.5.2021 21:24:00 CEST | Press release
Bagsværd, Denmark, 7 May2021 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S’ 2021 share repurchase programme of up to a total of DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. The transaction price is DKK 461.04 per share and has been calculated as the three-day volume weighted average market price from 5 May 2021 to 7 May 2021 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results. Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.5% of the share capital and 76.9% of the votes. Following the transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 116,129,000 B shares of DKK 0.20, corresponding to 28.3% of the capital and 76.8% of the votes in Novo Nordisk A/S. The transaction is in line with the announcement
RomReal: Mandatory notification of insider trade - Chairman and CEO of RomReal Kjetil Gronskag7.5.2021 19:34:48 CEST | Press release
Kjetil Gronskag, Chairman and CEO of RomReal Ltd has today 07 May 2021, purchased 2000 shares of RomReal at NOK 1.74 per share in RomReal Ltd. Following this trade, Kjetil Gronskag controls privately and through holding companies 4,546,127 shares in RomReal Ltd. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
PRFOODS NOTICE OF NOTEHOLDERS’ MEETING7.5.2021 16:58:01 CEST | Press release
AS PRFoods (registry code 11560713, registered address at Pärnu mnt 141, 11314 Tallinn, Estonia; “PRFoods”) hereby notifies persons holding the notes (the “Noteholders”) of the Issuer, due on 22 January 2025 and bearing ISIN code EE3300001577 (the “Notes”), issued under the Terms and Conditions of Secured Note Issue of AS PRFoods dated 14 January 2020 (which have been amended on 25 February 2020; the “Terms”), of convening a meeting of Noteholders (the “Meeting”). The Meeting will be held on 24 May 2021 at 12:00 (EET) at Peetri 12 (Kai Kunstikeskus), 10415 Tallinn, Estonia. Registration for the Meeting will be open at the venue of the Meeting from 11:00 to 11:45 (EET). The management of PRFoods requests all Noteholders to consider that due to COVID-19 caused by the coronavirus, it is advised to minimise the extent of physical gatherings and the participation therein. For this purpose, the management of PRFoods advises to consider authorising representatives of the collateral agent to p
AS PRFoods is Planning an Issue of Subordinated Convertible Notes and Tap-Issue of Secured Notes7.5.2021 16:44:03 CEST | Press release
THIS NOTICE IS NOT INTENDED FOR PUBLICATION, ALLOCATION OR TRANSMISSION, IN PART OR WHOLLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ELSEWHERE THE DISCLOSURE OR TRANSMISSION OF THIS INFORMATION IS NOT ALLOWED. AS PRFoods (registry code 11560713, “PRFoods”) announces that due to the continuing pandemic caused by COVID-19 and the extraordinary effects the pandemic and the measures implemented to combat the pandemic have had on the economic environment, including on the economic operations of PRFoods during the pending 2020/2021 financial year (i.e. the financial year 01.07.2020 – 30.06.2021), PRFoods deems necessary to reinforce its capital structure for the purposes of ensuring a smoother and faster recovery from the negative impacts caused by COVID-19 in the upcoming 2021/2022 financial year (i.e. financial year 01.07.2021 – 30.06.2022). In connection with the above, PRFoods hereby informs that, for the
CONDITIONS FOR PURCHASES OF CORPORATE BONDS7.5.2021 16:20:00 CEST | Press release
Bid procedure, 2021-05-12BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: ELLEVIO AB: XS1562583937, 2024-02-28 HUSQVARNA AB: SE0013359486, 2024-12-04 HUSQVARNA AB: SE0010869677, 2023-02-14 LUNDBERGFORETAGEN AB: SE0012676609, 2025-11-13 LUNDBERGFORETAGEN AB: SE0009241524, 2023-10-24 WILLHEM AB: SE0012193985, 2025-02-22 WILLHEM AB: SE0013882966, 2024-04-08 CASTELLUM AB: SE0011062827, 2023-05-17 CASTELLUM AB: SE0012675916, 2025-11-27 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2021-04-12Bid date2021-05-12Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS1562583937: 30 mln SEK +/-30 mln SEK SE0013359486: 30 mln SEK +/-30 mln SEK SE0010869677: 30 mln SEK +/-30 mln SEK SE0012676609: 30 mln SEK +/-30 ml
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS7.5.2021 16:20:00 CEST | Press release
Bid procedure, 2021-05-14BondsSWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01 SWEDEN I/L BOND: 3111, SE0007045745, 2032-06-01 Bid date2021-05-14Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3113: 500 mln SEK +/-250 mln SEK 3111: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)3113: 500 mln SEK per bid 3111: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-05-18Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-05-07 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be